Novavax, Inc. (NASDAQ:NVAX) – Equities research analysts at Seaport Global Securities raised their FY2017 earnings per share estimates for Novavax in a report released on Wednesday. Seaport Global Securities analyst V. Bernardino now anticipates that the biopharmaceutical company will earn ($0.60) per share for the year, up from their prior estimate of ($0.63). Seaport Global Securities has a “Neutral” rating on the stock. Seaport Global Securities also issued estimates for Novavax’s Q4 2017 earnings at ($0.14) EPS.
Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.01. The business had revenue of $8.35 million during the quarter, compared to the consensus estimate of $6.42 million. Novavax had a negative net margin of 726.35% and a negative return on equity of 787.38%. The firm’s quarterly revenue was up 158.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.24) earnings per share. TRADEMARK VIOLATION NOTICE: “FY2017 EPS Estimates for Novavax, Inc. (NVAX) Boosted by Analyst” was posted by Markets Daily and is owned by of Markets Daily. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.themarketsdaily.com/2017/11/15/fy2017-eps-estimates-for-novavax-inc-nvax-boosted-by-analyst.html.
Several other research firms also recently weighed in on NVAX. Cantor Fitzgerald reaffirmed a “hold” rating and set a $2.00 price target on shares of Novavax in a research note on Friday, July 21st. BidaskClub downgraded shares of Novavax from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. Zacks Investment Research downgraded shares of Novavax from a “buy” rating to a “hold” rating in a research note on Wednesday, July 26th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $1.50 price target on shares of Novavax in a research note on Wednesday, July 26th. Finally, Chardan Capital reaffirmed a “neutral” rating and set a $1.50 price target on shares of Novavax in a research note on Thursday, July 27th. One analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the stock. Novavax currently has a consensus rating of “Hold” and a consensus target price of $3.12.
Shares of Novavax (NASDAQ NVAX) opened at $1.19 on Monday. The company has a debt-to-equity ratio of -4.28, a current ratio of 3.31 and a quick ratio of 3.31. Novavax has a 12 month low of $0.73 and a 12 month high of $1.78.
Large investors have recently modified their holdings of the stock. Raymond James Financial Services Advisors Inc. raised its stake in Novavax by 49.8% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 89,697 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 29,800 shares in the last quarter. Profund Advisors LLC raised its stake in Novavax by 0.4% in the second quarter. Profund Advisors LLC now owns 120,775 shares of the biopharmaceutical company’s stock worth $139,000 after buying an additional 455 shares in the last quarter. Voya Investment Management LLC raised its stake in Novavax by 18.6% in the second quarter. Voya Investment Management LLC now owns 138,270 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 21,639 shares in the last quarter. HighTower Advisors LLC raised its stake in Novavax by 3.8% in the first quarter. HighTower Advisors LLC now owns 142,000 shares of the biopharmaceutical company’s stock worth $184,000 after buying an additional 5,250 shares in the last quarter. Finally, Brown Advisory Inc. raised its stake in Novavax by 74.8% in the third quarter. Brown Advisory Inc. now owns 162,700 shares of the biopharmaceutical company’s stock worth $185,000 after buying an additional 69,600 shares in the last quarter. 38.87% of the stock is owned by institutional investors.
In other Novavax news, insider Stanley C. Erck acquired 100,000 shares of Novavax stock in a transaction that occurred on Thursday, November 9th. The stock was bought at an average price of $1.13 per share, with a total value of $113,000.00. Following the completion of the purchase, the insider now directly owns 228,279 shares of the company’s stock, valued at approximately $257,955.27. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James F. Young sold 175,000 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $1.06, for a total transaction of $185,500.00. The disclosure for this sale can be found here. Insiders own 4.00% of the company’s stock.
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.